[전문]ICMS의 알앤엘바이오 줄기세포치료제 사망조사 결과

[아시아경제 신범수 기자]미국 성체줄기세포 학술단체인 ICMS는 14일 알앤엘바이오의 줄기세포치료제 사망사고와 관련한 조사결과를 발표했다.

사망한 1명은 줄기세포나 치료과정이 원인일 가능성이 낮다(unlikely)고 판단한 반면, 나머지 1명은 줄기세포 투여과정에 의해 사망이 야기됐거나 촉발됐을 가능성이 높다(likely)고 했다.

다음은 ICMS가 자체 홈페이지에 게재한 2명의 사망자의 사망원인에 대한 조사결과.

The death of Mr. Jun, which occurred nearly 2 months after his last stem cell infusion, was unlikely to have been caused by either the stem cells or the procedures used to administer the stem cells. The specific cause of Mr. Jun’s death is currently unknown as no documentation has been released with this information.

The death of Dr. Lim, which occurred on the same day as the stem cell procedure, was likely to have been caused or triggered by the stem cell procedure. The cause of death was due to a pre-existing blood clot that traveled to the lungs, and may have been precipitated by the procedure used to infuse the stem cells, or less probably, from a clot formed by the cells.

신범수 기자 answer@